share_log

Altimmune | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TANG CAPITAL PARTNERS, LP(5.1%),Tang Capital Management, LLC(5.1%), etc.

SEC announcement ·  Feb 14 16:03
Summary by Moomoo AI
On December 31, 2023, Tang Capital Partners, LP, along with Tang Capital Management, LLC, and Kevin Tang, collectively reported a shared voting and dispositive power over 2,750,000 shares of Altimmune, Inc.'s common stock, representing 5.1% of the company's class. This amendment was disclosed in a Schedule 13G/A filing with the Securities and Exchange Commission. The shares are beneficially owned by the reporting entities and person, with the percentages based on 53,728,871 shares of common stock outstanding as reported in Altimmune's Quarterly Report on November 3, 2023. The filing indicates that the ownership does not aim to change or influence the control of Altimmune, Inc. The information was certified as true and correct by Kevin Tang, Manager of Tang Capital Management, LLC, on February 14, 2024.
On December 31, 2023, Tang Capital Partners, LP, along with Tang Capital Management, LLC, and Kevin Tang, collectively reported a shared voting and dispositive power over 2,750,000 shares of Altimmune, Inc.'s common stock, representing 5.1% of the company's class. This amendment was disclosed in a Schedule 13G/A filing with the Securities and Exchange Commission. The shares are beneficially owned by the reporting entities and person, with the percentages based on 53,728,871 shares of common stock outstanding as reported in Altimmune's Quarterly Report on November 3, 2023. The filing indicates that the ownership does not aim to change or influence the control of Altimmune, Inc. The information was certified as true and correct by Kevin Tang, Manager of Tang Capital Management, LLC, on February 14, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more